Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review

Abstract Background: Major infectious disease outbreaks are a constant threat to human health. Clinical research responses to outbreaks generate evidence to improve outcomes and outbreak control. Experiences from previous epidemics have identified multiple challenges to undertaking timely clinical research […]

Click here to view original web page at Addressing challenges for clinical research responses to emerging epidemics and pandemics: a scoping review

No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY

Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on lopinavir-ritonavir, 29 June 2020 In March 2020, the RECOVERY trial was established as a randomised clinical trial to test a range of potential treatments […]

Click here to view original web page at No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

Click here to view original web page at Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial – The Lancet

One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results?

A World Health Organization–led global trial of treatments for COVID-19 was slow to enroll coronavirus-infected people, like this one in a Spanish intensive care unit, whereas a large trial in the United Kingdom quickly produced results for three treatments. […]

Click here to view original web page at One U.K. trial is transforming COVID-19 treatment. Why haven’t others delivered more results?

Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Objectives The coronavirus disease 2019 (COVID-19) pandemic has prompted many initiatives to identify safe and efficacious treatments, yet little is known regarding where early efforts have focused. We aimed to characterise registered clinical trials assessing drugs or plasma treatments […]

Click here to view original web page at Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis

Coronovirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

A phlebotomist draws blood from a patient participating in a clinical trial for a cancer treatment. With hospitals focused on COVID-19, hundreds of studies are being put on hold. Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for […]

Click here to view original web page at www.npr.org

Open Orphan PLC Q&A: Coronavirus challenge study model (LON:ORPH)

Open Orphan PLC (LON:ORPH ) Chief Executive Officer Cathal Friel caught up with DirectorsTalk for an exclusive interview to discuss the world’s first human coronavirus challenge study model. Q1: We’ve just seen that you’ve begun the development of the world’s first commercial human coronavirus challenge study model. What can […]

Click here to view original web page at www.directorstalkinterviews.com